Press release
Idiopathic Pulmonary Fibrosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight
Idiopathic Pulmonary Fibrosis Drugs Market
Unlock key insights into the Idiopathic Pulmonary Fibrosis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Idiopathic Pulmonary Fibrosis Therapeutics Market Outlook - https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report
In April 2025, Tvardi Therapeutics announced a study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
In April 2025, GlaxoSmithKline announced a study will assess the safety and effectiveness of GSK3915393 in IPF participants. Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
In April 2025, Boehringer Ingelheim announced a study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.
In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034).
Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.
In the epidemiological model of Idiopathic Pulmonary Fibrosis, cases in the 7MM for 2023 are categorized into age groups with 6,573 cases in the 18-39 years group, 24,492 in the 40-59 years group, 113,411 in the 60-79 years group, and 48,368 in those over 80 years, indicating a significant increase in prevalence with age.
In 2023, gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were higher in males, with approximately 120,718 cases, compared to females, who had around 73,152 cases, reflecting a higher prevalence in the male population.
The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.
Stay ahead in the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Idiopathic Pulmonary Fibrosis Treatment Market Size - https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM
Total Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases
Idiopathic Pulmonary Fibrosis Gender- specific Diagnosed Prevalent Cases
Idiopathic Pulmonary Fibrosis Age-specific Diagnosed Prevalent Cases
Idiopathic Pulmonary Fibrosis Severity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Prevalence- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Idiopathic Pulmonary Fibrosis Marketed Drugs
OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH
OFEV is a prescription drug for the treatment of IPF in adults. Nintedanib is the key ingredient and is a kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) a and ß, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3).
Idiopathic Pulmonary Fibrosis Emerging Drugs
BI 1015550: Boehringer Ingelheim
BI 1015550 is an investigational, oral phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects developed by Boehringer Ingelheim. BI 1015550 was studied as a monotherapy or in combination with background antifibrotic therapy to assess the effectiveness of slowing the rate of lung function decline in patients with Idiopathic Pulmonary Fibrosis. The accelerated development of BI 1015550 is part of Boehringer Ingelheim's next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients.
To learn more about Idiopathic Pulmonary Fibrosis Treatment guidelines, visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers - https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Idiopathic Pulmonary Fibrosis Drugs Market Insights
The main aim of treatment is to relieve the symptoms as much as possible and slow down its progression. There are two medicines that can help slow down the progression of idiopathic pulmonary fibrosis in people: ESBRIET (Pirfenidone) and OFEV (Nintedanib). Both drugs have shown to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies also shown decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and with pirfenidone rash, photosensitivity, and gastrointestinal discomfort. Gastrointestinal side effects are the most common reason for discontinuing both drugs.
Idiopathic Pulmonary Fibrosis Market Outlook
There are two antifibrotic agents approved for use in idiopathic pulmonary fibrosis. These are Pirfenidone and Nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.
Explore the dynamics of the Idiopathic Pulmonary Fibrosis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Idiopathic Pulmonary Fibrosis Ongoing Clinical Trials Analysis - https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Idiopathic Pulmonary Fibrosis Market Report
Coverage- 7MM
Study Period- 2020-2034
Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.
Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Idiopathic Pulmonary Fibrosis (IPF) Market Overview at a Glance
4 Idiopathic Pulmonary Fibrosis Epidemiology and Market Forecast Methodology
5 Key Events
6 Idiopathic Pulmonary Fibrosis Executive Summary
7 Idiopathic Pulmonary Fibrosis Market Disease Background and Overview
8 Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
9 Idiopathic Pulmonary Fibrosis Patient Journey
10 Idiopathic Pulmonary Fibrosis Marketed Drugs
11 Idiopathic Pulmonary Fibrosis Emerging Drugs
12 Idiopathic Pulmonary Fibrosis: Seven Major Market Analysis
13 Idiopathic Pulmonary Fibrosis KOL Views
14 Idiopathic Pulmonary Fibrosis SWOT Analysis
15 Idiopathic Pulmonary Fibrosis Unmet needs
16 Idiopathic Pulmonary Fibrosis Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
Trending Report:
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-epidemiology-forecast
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight here
News-ID: 4068402 • Views: …
More Releases from DelveInsight Business Research
Peanut Allergy Market Poised for Significant Growth from 2024 to 2034, Reports D …
DelveInsight's "Peanut Allergy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Peanut Allergy, historical and forecasted epidemiology as well as the Peanut Allergy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Peanut Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peanut Allergy Market Forecast
https://www.delveinsight.com/sample-request/peanut-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Usher Syndrome Market to Reach New Heights in Growth by 2034, DelveInsight Predi …
The Usher Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Usher Syndrome market dynamics.
DelveInsight's "Usher Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Usher Syndrome, historical and forecasted epidemiology as well as the Usher Syndrome market trends in the United States, EU5…
Underactive Bladder Market on Track for Major Expansion by 2034, According to De …
DelveInsight's "Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Underactive Bladder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Underactive Bladder Market Forecast
https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Tenosynovial Giant Cell Tumors Market to Expand Significantly by 2034, States De …
DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for Idiopathic
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
Juvenile Idiopathic Arthritis Therapeutics Market
JIA is also known as juvenile idiopathic arthritis and is the most common inflammatory arthritis of childhood, musculoskeletal pain is a common symptom in childhood and is usually benign and self-resolving. JIA is affected to children who are under age 17. Recognizing rare but treatable causes, including inflammatory, malignant and infectious etiologies, remains a constant challenge. According to the American College of Rheumatology, Juvenile idiopathic arthritis affects one in 1000…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
